Lexicon Pharmaceuticals I...

0.57
-0.00 (-0.09%)
At close: Mar 31, 2025, 10:58 AM
-0.09%
Bid 0.55
Market Cap 206.09M
Revenue (ttm) 32.97M
Net Income (ttm) -212.59M
EPS (ttm) -0.63
PE Ratio (ttm) -0.9
Forward PE -1.86
Analyst Hold
Ask 0.57
Volume 45,335,161
Avg. Volume (20D) 13,204,372
Open 0.57
Previous Close 0.57
Day's Range 0.55 - 0.71
52-Week Range 0.28 - 2.45
Beta 1.05

About LXRX

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The compan...

Industry Biotechnology
Sector Healthcare
IPO Date Apr 7, 2000
Employees 103
Stock Exchange NASDAQ
Ticker Symbol LXRX
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for LXRX stock is "Hold." The 12-month stock price forecast is $4, which is an increase of 601.63% from the latest price.

Stock Forecasts

Next Earnings Release

Lexicon Pharmaceuticals Inc. is scheduled to release its earnings on May 1, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
3 days ago
+64.13%
Lexicon Pharmaceuticals shares are trading higher ... Unlock content with Pro Subscription
3 weeks ago
-58.17%
Lexicon Pharmaceuticals shares are trading lower after the company announced topline results from its PROGRESS Phase 2b study of pilavapadin. Despite the study not meeting statistical significance in its primary endpoint, the 10 mg dose showed clear clinical benefits over placebo.